Abstract 5647: EGCG suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the VEGF/VEGFR axis

Abstract

Abstract The receptor tyrosine kinase (RTK) vascular endothelial growth factor (VEGF) receptor (VEGFR) plays an important role in tumor angiogenesis of hepatocellular carcinoma (HCC). (−)-Epigallocatechin gallate (EGCG), the major biologically active component of green tea, inhibits growth in a variety of human cancer cells by inhibiting the activation of several types of RTKs. In this study, we examined the effects of EGCG on the activity of the VEGF/VEGFR axis in human HCC cells. The levels of total and phosphorylated (i.e. activated) form of VEGFR-2 protein (p-VEGFR-2) were observed to increase in a series of human HCC cell lines in comparison to the Hc normal human hepatocytes. EGCG preferentially inhibited the growth of HuH7 HCC cells, which express the constitutive activation of the VEGF/VEGFR axis, in comparison to Hc cells. Treatment with HuH7 cells with EGCG caused a time- and dose-dependent decrease in the expression of VEGFR-2 and p-VEGFR-2 proteins. The production of VEGF from HuH7 cells was reduced by the treatment with EGCG. Drinking of EGCG significantly inhibited the growth of HuH7 xenografts in nude mice and this was associated with the inhibition of the activation of VEGFR-2 and its related downstream signaling molecules, including ERK and Akt. EGCG drinking also decreased the expression of Bcl-xL protein and VEGF mRNA in the xenografts. These findings suggest that EGCG can exert, at least in part, its growth inhibitive effect on HCC cells by inhibiting the VEGF/VEGFR axis. EGCG might therefore be useful in the treatment of HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5647.